The Recall Desk
ModerateFDA (Drugs)·D-1851-2019·Announced 2019-09-18

Macleods Recalls Pramipexole Dihydrochloride Tablets Due to Subpotency

Macleods Pharma USA is recalling Pramipexole Dihydrochloride Tablets 0.125 mg because stability studies showed the drug was subpotent.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class III, which indicates the violation is not likely to cause adverse health consequences. The hazard is subpotency, which is a quality issue rather than a direct safety hazard like contamination or injury.

Plain-English summary

Macleods Pharma USA Inc is recalling Pramipexole Dihydrochloride Tablets 0.125 mg, 90-count bottles. The recall involves 1,837 bottles of Lot #BPA801A with an expiration date of 12/2020. The product was distributed nationwide in the USA.

The recall was initiated because an out-of-specification result was found during a stability study, indicating the drug was subpotent. This means the tablets may not contain the full amount of the active ingredient required for effective treatment.

Consumers who have this specific lot of Pramipexole Dihydrochloride Tablets should stop using them and contact their healthcare provider or pharmacist for guidance on obtaining a replacement or alternative treatment.

The recalled product

Product
PRAMIPEXOLE DIHYDROCHLORIDE (PRAMIPEXOLE DIHYDROCHLORIDE)
Brand
PRAMIPEXOLE DIHYDROCHLORIDE

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot #BPA801A
  • EXP 12/2020

UPCs (5)

  • 0333342031105
  • 0333342035103
  • 0333342034106
  • 0333342033109
  • 0333342032102

Distribution

Distributed nationwide across the United States.

Same brand · PRAMIPEXOLE DIHYDROCHLORIDE